Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), a novel oral therapy for the treatment of moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older weighing at least 40 kg. The drug represents a significant advancement as the first and only targeted oral peptide designed to block the interleukin-23 (IL-23) receptor.
The approval marks a milestone in psoriasis treatment, offering a once-daily oral alternative to injectable biologics. ICOTYDE works by selectively inhibiting the IL-23 pathway, a key driver of inflammation in psoriasis. By targeting this mechanism with precision, the therapy aims to deliver effective skin clearance while maintaining a favorable safety profile.
Clinical data supporting the approval comes from the extensive ICONIC development program, which included four Phase 3 studies involving approximately 2,500 patients. The trials evaluated the therapy across a broad patient population, including both adults and adolescents, as well as individuals with psoriasis affecting high-impact areas such as the scalp and genital regions.
Results from the studies demonstrated strong efficacy. In head-to-head superiority trials, around 70% of patients treated with ICOTYDE achieved clear or almost clear skin, as measured by the Investigator’s Global Assessment (IGA 0/1) at Week 16. Additionally, 55% of patients reached a 90% improvement in the Psoriasis Area and Severity Index (PASI 90), a widely used benchmark for treatment success. Importantly, the therapy showed a safety profile comparable to placebo through 16 weeks, with no new safety concerns identified through one year of follow-up.
Experts say the approval could reshape the treatment landscape for psoriasis, a chronic inflammatory condition affecting more than 8 million people in the United States. While topical therapies are often the first line of treatment, many patients with moderate-to-severe disease require systemic options when initial approaches fail to provide sufficient relief.
The introduction of ICOTYDE aligns with evolving clinical guidance that encourages earlier transition to systemic therapies in appropriate patients. Its oral administration and targeted mechanism may improve treatment adherence and expand access to advanced care for patients who prefer to avoid injections.
Patient advocacy groups have also welcomed the development, noting that new treatment options are critical for addressing the diverse needs of individuals living with psoriasis. With its combination of efficacy, safety, and convenience, ICOTYDE is expected to play a key role in redefining treatment expectations for both patients and clinicians.